Linked Life Data

8870339

Source:http://linkedlifedata.com/resource/pubmed/id/8870339

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1996-12-5
pubmed:abstractText
The limitations of current therapies for atrial fibrillation are forcing a rethinking of how they should be used. Questions are being raised about the use of antiarrhythmic drugs, and new nonpharmacologic procedures are promising alternatives. Most patients with atrial fibrillation still require warfarin therapy, but some low-risk patients can forego it. Sinus rhythm spontaneously returns within the first 24 hours in almost half of cases of new atrial fibrillation. Patients with hemodynamic instability due to new-onset atrial fibrillation should proceed directly to electrical cardioversion. Warfarin therapy to maintain an International Normalized Ratio (INR) of 2.0 to 3.0 is currently recommended for all patients with atrial fibrillation with no contraindications to it, except for patients younger than 60 years with lone atrial fibrillation, in whom the risk of stroke is low. Certain antiarrhythmic drugs should be avoided in patients with congestive heart failure, in whom the risks may exceed the benefits. The maze procedure is emerging as an option to restore and maintain sinus rhythm. Radiofrequency atrioventricular node ablation and modification hold promise as options to control the ventricular rate without drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0891-1150
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
282-94
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Strategies for managing atrial fibrillation.
pubmed:affiliation
Cardiac Arrhythmia Service, New England Medical Center Hospitals, Boston, MA 02111, USA.
pubmed:publicationType
Journal Article, Review